- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06458907
TRICAV-II Pivotal: System zastawek TRIcvalve biCAVal do leczenia ciężkiej niedomykalności trójdzielnej. (TRICAV-II)
Prospektywne, wieloośrodkowe, randomizowane badanie kliniczne systemu przezcewnikowej zastawki dwudrożnej TricValve u pacjentów z ciężką niedomykalnością trójdzielną (TR).
Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Thuy Olender
- Numer telefonu: +1 408-839-3809
- E-mail: tolender@productsandfeatures.com
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85013
- St. Joseph's Hospital and Medical Center
-
-
California
-
Sacramento, California, Stany Zjednoczone, 95817
- UC Davis Health
-
San Diego, California, Stany Zjednoczone, 92037
- Scripps Memorial Hospital La Jolla
-
San Francisco, California, Stany Zjednoczone, 94143
- UCSF
-
San Jose, California, Stany Zjednoczone, 94118
- Kaiser Permanente
-
Główny śledczy:
- Andrew Rassi, MD
-
Kontakt:
- Cristina Casias
- Numer telefonu: 510-318-4224
- E-mail: cristina.casias@kp.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- MedStar Washington Hospital Center (MWHC)
-
Kontakt:
- Erin Collins
-
Główny śledczy:
- Toby Rogers, MD
-
-
Florida
-
Delray Beach, Florida, Stany Zjednoczone, 33484
- Delray Medical Center
-
Largo, Florida, Stany Zjednoczone, 33770
- HCA Florida Largo Hospital
-
Główny śledczy:
- Saurabh Sanon, MD
-
Kontakt:
- Holly-Lynn Grospitch
- Numer telefonu: 727-631-3721
- E-mail: hollylynn-grospitch@hcahealthcare.com
-
Tampa, Florida, Stany Zjednoczone, 33606
- Tampa General Hospital
-
-
Illinois
-
Glenview, Illinois, Stany Zjednoczone, 60026
- Endeavor Health
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46260
- Ascension Medical Group St. Vincent The Heart Center of Indiana
-
-
Kansas
-
Kansas City, Kansas, Stany Zjednoczone, 66103
- University of Kansas Medical Center
-
-
Louisiana
-
Houma, Louisiana, Stany Zjednoczone, 70360
- Cardiovascular Institute of the South
-
Główny śledczy:
- Peter Fail, MD
-
Kontakt:
- Jenny Aucoin
- Numer telefonu: 985-873-5037
- E-mail: jennifer.aucoin@cardio.com
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital
-
Burlington, Massachusetts, Stany Zjednoczone, 01805
- Lahey Hospital & Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64111
- Saint Luke's Mid America Heart Institute
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University of St Louis
-
-
New Jersey
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center
-
-
New York
-
Manhasset, New York, Stany Zjednoczone, 11030
- Northwell Hospital
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone, 44106
- Cleveland Clinic
-
Główny śledczy:
- Rishi Puri, MD
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Riverside Methodist Hospital
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health
-
Główny śledczy:
- Firas Zahr, MD
-
Kontakt:
- Halie Ropp
- Numer telefonu: 503-494-1147
- E-mail: ropph@ohsu.edu
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- MUSC
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Houston Methodist
-
Houston, Texas, Stany Zjednoczone, 77030
- University of Texas (Memorial Hermann)
-
Plano, Texas, Stany Zjednoczone, 75093
- Baylor Scott & White Medical
-
-
Utah
-
Murray, Utah, Stany Zjednoczone, 84107
- Intermountain Heart Institute - Intermountain Medical Center
-
Główny śledczy:
- Brian Whisenant, MD
-
Kontakt:
- McKenna Jensen
- Numer telefonu: 801-917-0978
- E-mail: mcKenna.jensen@imail.org
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22903
- UVA School of Medicine
-
Norfolk, Virginia, Stany Zjednoczone, 23507
- Sentara Healthcare
-
Roanoke, Virginia, Stany Zjednoczone, 24014
- Carilion Clinic
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Eligibility Criteria for Randomized Cohort:
Inclusion Criteria:
- Age between 18 years and 85 years old, at the time of signing the informed consent.
- Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
- NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
- Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
- High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
- Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
- For females of childbearing potential, negative pregnancy test.
- Capable and willing to provide signed informed consent
Exclusion Criteria:
CONCOMITANT PROCEDURES
-
Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
-
Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.
CARDIOVASCULAR CONDITIONS
-
LVEF ≤ 30% on echocardiography.
-
Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
-
Severe right ventricular dysfunction.
-
Cardiac amyloidosis.
-
Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
-
Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.
-
Hemodynamically significant pericardial effusion.
-
Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
-
Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).
-
Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.
ALLERGIES / INTOLERANCE
-
Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.
-
Unable to tolerate anticoagulation/antiplatelet therapy
COMORBIDITIES
-
Any known life-threatening condition with an estimated life span of less than 12 months.
-
Platelet count < 75,000/mm3
-
Child-Pugh Severity Class C (10-15 points).
-
Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
-
Endocarditis or active/ongoing infection requiring antibiotics.
-
Unable to walk at least 100 meters in a 6-minute walk test.
-
Known bleeding or clotting disorders or patient refuses blood transfusion.
-
Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.
-
Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria
a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.
b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.
GENERAL EXCLUSIONS
-
Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
-
Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.
-
Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
-
Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.
Eligibility Criteria for Single Arm Cohort:
Inclusion Criteria:
- Age > 85 years.
- NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
- LVEF ≤ 30% on echocardiography.
- Severe RV dysfunction.
- Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
- Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
- Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
- Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
- Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: TricValve System + Optimal medical therapy (OMT)
Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation. |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
Inne nazwy:
Optimal medical therapy
Inne nazwy:
|
|
Aktywny komparator: Optimal medical therapy (OMT) Alone
OMT alone in patients with caval reflux and tricuspid regurgitation |
Optimal medical therapy
Inne nazwy:
|
|
Eksperymentalny: TricValve Single Arm Registry
Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
Inne nazwy:
Optimal medical therapy
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Randomized Cohort: Caval Reflux (CR) grade reduction
Ramy czasowe: 6 months
|
Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better. |
6 months
|
|
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
Ramy czasowe: 6 months
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
6 months
|
|
Randomized Cohort: Rate of Major Adverse Events (MAE)
Ramy czasowe: 30 days
|
Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT) |
30 days
|
|
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
Ramy czasowe: 1 year
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
1 year
|
|
Registry Cohort: Rate of Major Adverse Events (MAE)
Ramy czasowe: 30 days
|
Rate of Major Adverse Events (MAE) in single arm registry |
30 days
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
Ramy czasowe: 1 year
|
Rate of Major Adverse Events |
1 year
|
|
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
Ramy czasowe: 6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Randomized Cohort: Heart Failure Hospitalizations (HFH)
Ramy czasowe: 6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitilization |
6 months and 1 year
|
|
Randomized Cohort: RVAD Implantation or Heart Transplant
Ramy czasowe: 6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Randomized Cohort: Atrial Fibrillation
Ramy czasowe: 1 year
|
New onset of atrial fibrillation |
1 year
|
|
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
Ramy czasowe: 6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
6 months and 1 year
|
|
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
Ramy czasowe: 6 months and 1 year
|
Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
Ramy czasowe: 6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
|
Registry Cohort: Heart Failure Hospitalization
Ramy czasowe: 1 year
|
Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate |
1 year
|
|
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
Ramy czasowe: 1 year
|
Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
1 year
|
|
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
Ramy czasowe: 1 year
|
Rate of Major Adverse Events |
1 year
|
|
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
Ramy czasowe: 6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
Ramy czasowe: 6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitalization |
6 months and 1 year
|
|
Roll-In Cohort: RVAD Implantation or Heart Transplant
Ramy czasowe: 6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Roll-In Cohort: Atrial Fibrillation
Ramy czasowe: 1 year
|
New onset of atrial fibrillation |
1 year
|
|
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
Ramy czasowe: 6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life |
6 months and 1 year
|
|
Roll-In Cohort: New York Heart Association (NYHA) functional class
Ramy czasowe: 6 months and 1 year
|
Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Roll-In Cohort: 6-minute walk test (6MWT).
Ramy czasowe: 6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Publikacje i pomocne linki
Publikacje ogólne
- Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Blasco-Turrion S, Sanchez-Luna JP, Revilla-Orodoea A, Redondo A, Zamorano JL, Puri R, Iniguez-Romo A, San Roman A. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023 Aug 7;19(5):e450-e452. doi: 10.4244/EIJ-D-23-00077. No abstract available.
- Blasco-Turrion S, Briedis K, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Sanchez-Luna JP, Gonzalez-Gutierrez JC, Revilla-Orodoea A, Zamorano JL, Gomez-Salvador I, Puri R, San Roman JA, Amat-Santos IJ. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes. JACC Cardiovasc Interv. 2024 Jan 8;17(1):60-72. doi: 10.1016/j.jcin.2023.10.043. Epub 2023 Dec 6.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- CTP-TRIC-005-II
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .